Incyte Corp
NASDAQ:INCY

Watchlist Manager
Incyte Corp Logo
Incyte Corp
NASDAQ:INCY
Watchlist
Price: 68.82 USD 2.62%
Market Cap: 13.3B USD
Have any thoughts about
Incyte Corp?
Write Note

Incyte Corp
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Incyte Corp
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Incyte Corp
NASDAQ:INCY
Pre-Tax Income
$273.9m
CAGR 3-Years
-24%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Incyte Corp
Glance View

Market Cap
13.3B USD
Industry
Biotechnology
Economic Moat
None

Incyte Corporation stands as a significant player in the biopharmaceutical landscape, where its roots are firmly planted in the research and development of novel therapeutics. Founded in 1991, Incyte initially carved its path focusing on genomics before pivoting towards drug development. This transformation catalyzed its growth, anchored by its commitment to discovering innovative ways to tackle unmet medical needs in oncology and inflammation. The company’s forte lies in its robust pipeline of targeted therapies, leveraging small molecules and monoclonal antibodies to alter the course of diseases. Incyte's approach is driven by a deep understanding of the biological pathways that underpin human health, allowing it to develop medicines that offer new hope to patients suffering from debilitating conditions. Incyte's commercial success is largely attributed to its flagship product, Jakafi (ruxolitinib), a groundbreaking oral selective inhibitor of Janus Associated Kinases (JAK1 and JAK2). Approved for the treatment of specific types of myelofibrosis and polycythemia vera, Jakafi represents a crucial revenue stream for the corporation. Beyond Jakafi, Incyte has been fruitful in diversifying its portfolio, fostering collaborative partnerships, and strategically licensing its assets to expand market reach and share risks. This dual strategy of internal innovation and external collaboration not only fuels Incyte’s financial engine but also reinforces its position in a competitive marketplace, as it continuously seeks out new frontiers in medical science to address complex diseases worldwide.

INCY Intrinsic Value
88.27 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Incyte Corp's Pre-Tax Income?
Pre-Tax Income
273.9m USD

Based on the financial report for Sep 30, 2024, Incyte Corp's Pre-Tax Income amounts to 273.9m USD.

What is Incyte Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-9%

Over the last year, the Pre-Tax Income growth was -57%. The average annual Pre-Tax Income growth rates for Incyte Corp have been -24% over the past three years , -9% over the past five years .

Back to Top